Advice
in the absence of a submission from the holder of the marketing authorisation
afatinib (Giotrif®) is not recommended for use within NHS Scotland.
Indication under review: As monotherapy for the treatment of locally advanced or metastatic non small cell lung cancer of squamous histology progressing on or after platinum-based chemotherapy.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.
Download detailed advice110KB (PDF)
Medicine details
- Medicine name:
- afatinib (Giotrif)
- SMC ID:
- 1174/16
- Indication:
- As monotherapy for the treatment of locally advanced or metastatic non small cell lung cancer of squamous histology progressing on or after platinum-based chemotherapy.
- Pharmaceutical company
- Boehringer Ingelheim Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 11 July 2016